A Study to Evaluate the Pharmacodynamic, Efficacy and Safety of SHR-1703 in Asthma Patients With Eosinophil Phenotype

NCT05522439 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

85

Enrollment

INDUSTRY

Sponsor class

Conditions

Asthma With Eosinophilic Phenotype

Interventions

DRUG: SHR-1703
DRUG: SHR-1703 Placebo

Sponsor

Jiangsu HengRui Medicine Co., Ltd.